Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.48 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | S100A4 | P26447 | 1/20 | 0.39 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29954306 | 1.00 | TDP1 (0.48) | TDP1GPR35TSHRSMN1; SMN2ERN1 | |
| SCHEMBL28117 | 0.80 | HSD17B10 (0.54) | TDP1GPR35TSHRSMN1; SMN2ERN1 | |
| SCHEMBL29614987 | 0.80 | HSD17B10 (0.54) | TDP1GPR35TSHRSMN1; SMN2ERN1 | |
| SCHEMBL3010961 | 0.80 | TDP1 (0.61) | TDP1GPR35TSHRSMN1; SMN2ERN1 | |
| SCHEMBL6500391 | 0.79 | TDP1 (0.67) | TDP1GPR35TSHRSMN1; SMN2ERN1 | |
| SCHEMBL29956172 | 0.79 | TDP1 (0.67) | TDP1GPR35TSHRSMN1; SMN2ERN1 | |
| SCHEMBL12481082 | 0.78 | TDP1 (0.36) | TDP1GPR35TSHRSMN1; SMN2ERN1 | |
| SCHEMBL22206200 | 0.78 | TDP1 (0.48) | TDP1GPR35TSHRSMN1; SMN2ERN1 | |
| SCHEMBL16919346 | 0.78 | TDP1 (0.48) | TDP1GPR35TSHRSMN1; SMN2ERN1 | |
| Ammonia Solution, Strong SCHEMBL28763100 | 0.78 | TDP1 (0.58) | TDP1GPR35TSHRSMN1; SMN2ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3981839-B1 | COELENTERAZINE ANALOGS FOR USE IN LUCIFERASE-BASED ASSAYS | PROMEGA CORP (US) | 2025-08-20 | — | — | EP | disclosed |
| WO-2025064210-A1 | INHIBITORS OF BILIVERDIN REDUCTASE B (BLVRB) | BLOOD CELL TECHNOLOGIES, LLC (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20240059697-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2024-02-22 | — | — | US | disclosed |
| CN-112513188-B | Coelenterazine analogs | 普洛麦格公司 | 2024-01-26 | — | — | CN | disclosed |
| US-11691976-B2 | Coelenterazine analogues | PROMEGA CORPORATION (US) | 2023-07-04 | — | — | US | disclosed |
| EP-3841173-A1 | COELENTERAZINE ANALOGUES | Promega Corporation (US) | 2021-06-30 | — | — | EP | disclosed |
| CN-112513188-A | Coelenterazine analogs | 普洛麦格公司 | 2021-03-16 | — | — | CN | disclosed |
| US-20200062766-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2020-02-27 | — | — | US | disclosed |
| WO-2020041579-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION (US) | 2020-02-27 | — | — | WO | disclosed |
| EP-2661433-B1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2017-08-16 | — | — | EP | disclosed |
| CN-105837572-A | N-substituted phenylacrylamide derivative and its preparation method and purpose | 四川大学 | 2016-08-10 | — | — | CN | disclosed |
| EP-2718264-B1 | BENZOCYCLOHEPTENE ACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2015-08-05 | — | — | EP | disclosed |
| US-9085555-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-07-21 | — | — | US | disclosed |
| CN-103402996-B | Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (AMD) | NOVARTIS AG | 2015-02-11 | — | — | CN | disclosed |
| EP-2718264-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-04-16 | — | — | EP | disclosed |
| EP-2661433-A1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | Novartis AG (CH) | 2013-11-13 | — | — | EP | disclosed |
| WO-2012168162-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | disclosed |
| US-20120309796-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | FIROOZNIA FARIBORZ (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2012-11-22 | — | — | US | disclosed |
| WO-2012093101-A1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2012-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062766-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | TDP1 3852/4885GPR35 196/4885TSHR 2341/4885 |
| US-11691976-B2 | Coelenterazine analogues | GLB1, SI, TCF7L2 | TDP1 3852/4885GPR35 196/4885TSHR 2341/4885 |
| US-20240059697-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | TDP1 3852/4885GPR35 196/4885TSHR 2341/4885 |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | C5, C3AR1, C9 | TDP1 4428/4885GPR35 286/4885TSHR 2475/4885 |
| US-20120309796-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | ACAT2, ACAT1, CYP27A1 | TDP1 4067/4885GPR35 555/4885TSHR 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.